{"nctId":"NCT01004432","briefTitle":"Golimumab in Rheumatoid Arthritis Participants With an Inadequate Response to Etanercept (ENBREL) or Adalimumab (HUMIRA)","startDateStruct":{"date":"2009-12"},"conditions":["Arthritis","Arthritis, Rheumatoid","Autoimmune Diseases"],"count":433,"armGroups":[{"label":"Open-label (OL) Overall Group: Golimumab 50 mg SC + MTX","type":"EXPERIMENTAL","interventionNames":["Drug: Golimumab 50 mg SC","Drug: Methotrexate (MTX)"]},{"label":"Double blind (DB) Group 2a: Golimumab 50mg SC & Placebo IV+MTX","type":"EXPERIMENTAL","interventionNames":["Drug: Golimumab 50 mg SC","Drug: Methotrexate (MTX)","Drug: Placebo IV"]},{"label":"DB Group 2b: Golimumab 2mg/kg IV & Placebo SC + MTX","type":"EXPERIMENTAL","interventionNames":["Drug: Golimumab 2 mg/kg IV","Drug: Methotrexate (MTX)","Drug: Placebo SC"]},{"label":"OL Group 1: Golimumab 50 mg SC + MTX","type":"EXPERIMENTAL","interventionNames":["Drug: Golimumab 50 mg SC","Drug: Methotrexate (MTX)"]},{"label":"OL Study Extension Group: Golimumab 50 mg SC + MTX","type":"EXPERIMENTAL","interventionNames":["Drug: Golimumab 50 mg SC","Drug: Methotrexate (MTX)"]}],"interventions":[{"name":"Golimumab 50 mg SC","otherNames":[]},{"name":"Golimumab 2 mg/kg IV","otherNames":[]},{"name":"Methotrexate (MTX)","otherNames":[]},{"name":"Placebo SC","otherNames":[]},{"name":"Placebo IV","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Have inadequate RA disease control prior to the first administration of study agent despite treatment with etanercept (Enbrel) + methotrexate or adalimumab (Humira) + methotrexate (MTX)\n* Must have received a stable dose of MTX greater than or equal to (\\>=) 7.5 milligram (mg) per week to less than or equal to (\\<=) 25 mg per week for at least 4 consecutive weeks prior to the first screening visit and must plan to maintain that dose throughout the study\n* Participants must have received etanercept or adalimumab in combination with MTX for a minimum of 3 months prior to the first visit\n* Negative tuberculosis (TB) test\n* Are capable of providing informed consent, which must be obtained prior to any study-related procedures\n\nExclusion Criteria:\n\n* Have a history of latent or active granulomatous infection, including TB, histoplasmosis, or coccidioidomycosis, or are frequently in contact with individuals who carry active TB infection\n* Have inflammatory diseases other than RA, including but not limited to psoriatic arthritis, ankylosing spondylitis, systemic lupus erythematosus, primary Sjogren's or Lyme disease\n* Have demonstrated a discernible improvement in disease activity between screening and prior to the first golimumab injection at Week 0\n* Have any known malignancy or have a history of malignancy within the previous 5 years (with the exception of a nonmelanoma skin cancer that has been treated with no evidence of recurrence)\n* Have a history of lymphoproliferative disease, including lymphoma, or signs and symptoms suggestive of possible lymphoproliferative disease such as lymphadenopathy of unusual size or location","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants Achieving Erythrocyte Sedimentation Rate (ESR)-Based American College of Rheumatology [ACR] 20 Response at Week 14","description":"Erythrocyte Sedimentation Rate (ESR)-based ACR 20 response: greater than or equal to (\\>=) 20 percent (%) improvement from Baseline in tender (68 joints assessed) and swollen (66 joints assessed) joint counts and \\>=20% improvement from Baseline in 3 of the following 5 assessments: 1- Participant's assessment of pain using Visual Analog Scale (VAS) (0 to 10 centimeters \\[cm\\]), 2- Participant's global assessment of disease activity using VAS (0 to 10 cm), 3- Physician's global assessment of disease activity using VAS (0 to 10 cm), 4- Participant's assessment of physical function as measured by the Disability Index of the Health Assessment Questionnaire (HAQ-DI) (score of 0-3 in 8 functional areas), 5- ESR.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"34.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Achieved Erythrocyte Sedimentation Rate (ESR)-Based ACR20 Response at Week 2","description":"Erythrocyte Sedimentation Rate (ESR)-based ACR 20 response: greater than or equal to (\\>=) 20 percent (%) improvement from Baseline in tender (68 joints assessed) and swollen (66 joints assessed) joint counts and \\>=20% improvement from Baseline in 3 of the following 5 assessments: 1- Participant's assessment of pain using Visual Analog Scale (VAS) (0 to 10 centimeters \\[cm\\]), 2- Participant's global assessment of disease activity using VAS (0 to 10 cm), 3- Physician's global assessment of disease activity using VAS (0 to 10 cm), 4- Participant's assessment of physical function as measured by the Disability Index of the Health Assessment Questionnaire (HAQ-DI) (score of 0-3 in 8 functional areas), 5- ESR.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"24.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Achieved Erythrocyte Sedimentation Rate (ESR)-Based Disease Activity Score (DAS28) Response at Week 16 and Maintained Response Through Week 52","description":"Erythrocyte Sedimentation Rate (ESR)-based disease activity score for 28-joints count (DAS28) as defined by European League Against Rheumatism (EULAR), response criteria was used to assess individual response as none, moderate, or good, depending on the extent of change from Baseline and the level of disease activity reached. A participant was classified as having achieved a DAS28 good response if, DAS28 was less than or equal to (\\<=) 3.2 at a given visit and improvement from Baseline was \\>1.2. Percentage of participants, who achieved ESR-based DAS 28 good response at Week 16 and maintained that response through Week 52, is reported.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Achieved Erythrocyte Sedimentation Rate (ESR)-Based ACR20 Response at Week 52 Relative to Week 16","description":"Erythrocyte Sedimentation Rate (ESR)-based ACR 20 response: \\>=20 % improvement from Week 16 in tender (68 joints assessed) and swollen (66 joints assessed) joint counts and \\>=20% improvement from Week 16 in 3 of the following 5 assessments: 1- Participant's assessment of pain using VAS (0 to 10 cm), 2- Participant's global assessment of disease activity using VAS (0 to 10 cm), 3- Physician's global assessment of disease activity using VAS (0 to 10 cm), 4- Participant's assessment of physical function as measured by the Disability Index of the Health Assessment Questionnaire (HAQ-DI) (score of 0-3 in 8 functional areas), 5- ESR. Percentage of participants, who achieved ESR-based ACR 20 responses at Week 52 relative to Week 16, is reported.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13.2","spread":null},{"groupId":"OG001","value":"9.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Achieved ESR-based and C-Reactive Protein (CRP)-Based ACR20 Response at Week 76 Relative to Week 16","description":"Erythrocyte Sedimentation Rate (ESR)-based/ C Reactive Protein (CRP)-based ACR 20 response: \\>=20 % improvement from Week 16 in tender (68 joints assessed) and swollen (66 joints assessed) joint counts and \\>=20% improvement from Week 16 in 3 of the following 5 assessments: 1- Participant's assessment of pain using VAS (0 to 10 cm), 2- Participant's global assessment of disease activity using VAS (0 to 10 cm), 3- Physician's global assessment of disease activity using VAS (0 to 10 cm), 4- Participant's assessment of physical function as measured by the Disability Index of the Health Assessment Questionnaire (HAQ-DI) (score of 0-3 in 8 functional areas), 5- ESR or CRP. Percentage of participants, who achieved ESR/ CRP-based ACR 20 responses at Week 76 relative to Week 16, is reported.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.9","spread":null},{"groupId":"OG001","value":"8.5","spread":null},{"groupId":"OG002","value":"15.7","spread":null},{"groupId":"OG003","value":"11.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.9","spread":null},{"groupId":"OG001","value":"8.5","spread":null},{"groupId":"OG002","value":"17.6","spread":null},{"groupId":"OG003","value":"12.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in ESR-based DAS28 Score at Week 76 Relative to Week 52","description":"Erythrocyte Sedimentation Rate (ESR)-based disease activity score for 28-joints count (DAS28) was calculated from number of swollen joint counts (SJC) and tender joint counts (TJC) using 28 joints count, ESR, and patient global assessment of disease activity (participant rated arthritis activity assessment with scores ranging 0 to 10; higher scores indicated greater disease activity). Total ESR-based DAS28 score range: 0 to 9.4, higher score=more disease activity.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.182","spread":"1.1109"},{"groupId":"OG001","value":"4.070","spread":"0.8037"},{"groupId":"OG002","value":"4.394","spread":"1.2389"},{"groupId":"OG003","value":"3.950","spread":"1.2379"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.136","spread":"1.2095"},{"groupId":"OG001","value":"0.209","spread":"1.2253"},{"groupId":"OG002","value":"-0.017","spread":"1.0518"},{"groupId":"OG003","value":"-0.013","spread":"1.1386"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":20,"n":433},"commonTop":["Upper respiratory tract infection","Urinary tract infection","Sinusitis","Arthralgia","Rheumatoid arthritis"]}}}